

YOUR SMILE. **OUR VISION**.

# **FY19 RESULTS PRESENTATION**

Samantha Cheetham CEO John Slaviero CFO / COO

# Your Smile. Our Vision.



Long successful operating history – founded in 1972 and listed on ASX in 1985 and Australia's largest dental manufacturer



SDI conducts research and development of specialist dentist materials undertaking the development, manufacturing and marketing of dental restorative materials.



SDI sells to 100+ countries on all continents and with sales teams and distribution in Australia, Brazil, Europe and North America



# **AGENDA**

- FY19 highlights
- Product categories
- Key geographies
- Financial performance
- Strategy and outlook








# **FY19 Highlights**

- Total sales up 6.8% to \$79.6m
- **Gross margins** up 2.3% to 62.6%, due to the favourable product mix and currency
- **EBITDA** growth of 16.7%
- **NPAT up 29.5%** to \$7.3m

- Aesthetic sales (42.7% of sales) up 11.6% in local currency
- Strong cash generation and no net debt
- Total dividends for FY19, including a special dividend in 1H19, increased by 48% to 3.7 cents


#### Sales v EBITDA (\$m)



# STRONG FREE CASHFLOW AND NO DEBT

Strong financial position enables continued to grow in the business

 Free cash to invest in the business, new machinery and product development.








# PRODUCT CATEGORIES





## Research & Development / Product Mix

- Continue to invest in Research and Development with \$2.6m spent in FY19
- Aesthetics and whitening products now represent 70% of all sales
- 70% of Intangibles are Aesthetics products, including Glass Ionomers and Composites





### **AESTHETICS GROWTH AHEAD OF MARKET**

- Aesthetics sales performed strongly, up 11.6% in local currency
- Whitening sales, now 26.9% of total sales, were up 3.2% in local currency
- Equipment sales, which are used to drive other product sales, were down 4.1% in local currency
- Amalgam sales, declined 10.1% in local currency, continuing the trend we have seen in recent years

Product Category Sales	Growth in Local Currency	Growth in AUD	% of Total AUD Sales
Aesthetics	11.6%	16.3%	42.7%
Whitening	3.2%	7.6%	26.9%
Equipment	(4.1)%	(1.8)%	7.6%
Amalgam	(10.1)%	(5.8)%	22.8%







# KEY GEOGRAPHIES



YOUR SMILE. OUR VISION.

# Sales by business unit and product

- The Australian business sales grew by 12.1in local currency, with direct exports to Middle East and Asia notably stronger
- North American sales saw a 1.5% decline, impacted by a 11.2% decline in Amalgam represents 34.4% of the amalgam sales
- This region also saw a 4.4% increase in other category sales, which represent 65.6% of sales

- European sales fell 3.5% impacted by a 22.1% decline in Amalgam which make up 17.9% of the region's sales.
- In the other product category we saw growth of 1.9%, which make up 82.1% of Europe sales

Business Units	% Growth in Local Currency	% Growth in AUD	% of AUD Sales
Australia*	12.1	17.1	38,4
North America	(1.5)	6.3	24.1
Europe	(3.5)	(0.1)	31.1
Brazil	(3.4)	(10.0)	6.4
Total	2.5	6.8	100.0

\*includes direct exports

Business Units	Amalgam (AUD)		Aesthetics/Whitening/Equipment (AUD)		
	% Chg	% Sales	% Chg	% Sales	
Australia*	3.3	18.2	14.2	81.8	
North America	(11.2)	34.4	4.4	65.6	
Europe	(22.1)	17.9	1.9	82.1	
Brazil	(7.5)	29.8	(1.6)	70.2	
Total	(5.8)	22.8	11.6	77.2	

\*includes direct exports





# **GEOGRAPHICAL SALES FY19 (AUD)**

North America \$19.2m: +6.3%


Europe \$27.6m: (1.3)%

Middle East / Africa \$8.7m: +35.5%

South America \$9.4m: +1.6%

> APAC \$14.7m: +13.8%







# FINANCIAL PERFORMANCE



YOUR SMILE. OUR VISION.

## **Profit & Loss**

Profit & Loss (\$'000)	FY19	FY18	Change
Revenue			
Sales revenue	79,598	74,535	6.8%
Cost of goods sold	(29,805)	(28,966)	2.9%
Gross profit	49,793	45,569	9.3%
Gross margin	62.6%	61.1%	
Expenses			
Selling and administration expenses	(37,883)	(34,231)	10.7%
Research and development costs	(1,015)	(1,253)	(19.0%)
Other expenses	(1,312)	(1,976)	(33.6%)
Profit before tax	10,484	8,145	28.7%
Tax expense	(3,155)	(2,484)	27.0%
Net profit after tax	7,329	5,661	29.5%
Depreciation & Amortisation	(3,669)	(3,868)	(5.1%)
Net interest expense	(24)	(135)	(82.2%)
EBITDA	14,177	12,148	16.7%

#### Sales:

•F/X adj increased by 2.5%

#### **Gross Profit:**

•F/X adj 61.1%

#### **S&A Exp:** increased \$3.7m, incl:

- Additional Selling & Marketing \$1.5m
- •F/X unfavourable effect on expenses \$0.9m
- International Dental Show \$0.3m
- **LTI \$0.4m**

#### R&D:

includes \$0.9m Amortisation & a lower research expense

#### **FY18 Other**

•included \$0.3m Currency Loss

#### **Total Exp:**

F/X adj increased by 5.1%



### **Balance Sheet**

Balance sheet (\$'000)	FY19	FY18	Change
Assets			
Cash and cash equivalents	6,481	8,246	(21.4%)
Trade and other receivables	18,596	16,225	14.6%
Inventories	17,242	14,558	18.4%
Prepayments	1,100	750	46.7%
Other receivables	713	885	(19.4%)
Property, plant and equipment	18,680	17,569	6.3%
Intangibles	24,603	23,657	4.0%
Total assets	87,415	81,890	6.7%
Liabilities			
Trade and other payables	7,077	3,957	78.8%
Borrowings	-	2,214	(100.0%)
Provision for income tax	1,386	182	661.5%
Employee benefits	3,516	3,546	(0.8%)
Deferred tax liability	2,363	2,437	(3.0%)
Total liabilities	14,342	12,336	16.3%
Net assets	73,073	69,554	5.1%

#### Cash

- Debt reduction \$2.2m
- •Inventory increase \$2.7m
- P &E increase \$1.3m
- Dividend payment increase \$1.4m

#### Receivables

•21% increase in Aust. direct exports, longer payment terms

#### **Inventory**

Improve customer service, reduce air freight costs, meet sales expectations of existing and new products

#### **Creditors**

Purchase of raw materials for large sales in May & June.




## **Cash Flow**

Cashflow statement (\$'000)	FY19	FY18	Change
Receipts from customers	77,399	74,000	4.6%
Payments to suppliers and employees	(64,905)	(60,264)	7.7%
Other revenue	58	36	61.1%
Interest and other finance costs paid	(37)	(163)	(77.3%)
Income taxes paid	(2,025)	(2,319)	(12.7%)
Net cash from operating activities	10,503	11,290	(7.0%)
Payments for PP&E	(3,146)	(1,824)	72.5%
Payments for intangibles	(2,706)	(2,346)	15.3%
Proceeds from disposal of PP&E	158	43	267.4%
Net cash used for investing activities	(5,694)	(4,127)	38.0%
Cash flows used in financing activities	(6,493)	(4,776)	36.0%
Cash & cash equivalents - end of period	6,491	8,246	(21.3%)

- Increase in sales
- Increase in inventories & operating expenses
- New machinery for new product lines & upgrade of existing machinery to improve automation
- Increasing R&D development project expenditure
- \$1.4m increase dividend payments
- \$2.2m of debt repayment





# STRATEGY & OUTLOOK



YOUR SMILE. **OUR VISION**.

# REBRANDING / PROMOTIONAL INVESTMENTS

#### Sales and Marketing

- Increased global salesforce
- Strategic corporate rebranding positioning SDI as an innovator
- •Investment in key opinion leaders
- Additional distributor and dentist training
- Increase in promotional materials and selling tools

### International Dental Show (IDS)

- World's largest dental exhibition held biennially
- Global meeting point for the dental industry
- Presentations to dentists and distributors from over 100 countries
- Launched new products





### STRATEGY & OUTLOOK

#### Strategic priorities/progress:

- Rationalise product portfolio
  - Plans to reduce the number of SKUs by 30% on track
- ❖ Focus on key product categories whitening, glass ionomers and composites
  - Launched new products at the IDS
- Drive amalgam replacement
  - Commonwealth Govt grant \$3m awarded in August 2019
- Increase innovation and speed to market
  - Investment in new product machinery
  - Riva Star research findings compelling

#### **FY20 Plans:**

- Complete rationalisation of product portfolio
- Brazil manufacturing starting September 2019
- \$3m planned investment on further machine automation and product development
- In FY20, we expect continued sales growth in Aesthetics and Whitening products in line with previous years (70% of sales)







#### **DISCLAIMER**

THIS PRESENTATION CONTAINS SUMMARY INFORMATION ABOUT SDI LIMITED ISDIN AND ITS SUBSIDIARIES AND THEIR ACTIVITIES. THE INFORMATION IN THIS PRESENTATION DOES NOT PURPORT TO BE COMPLETE. IT SHOULD BE READ IN CONJUNCTION WITH SDI'S OTHER PERIODIC AND CONTINUOUS DISCLOSURE ANNOUNCEMENTS LODGED WITH THE

AUSTRALIAN SECURITIES SHOULD SEALCH AND C. WHIS PRESIDENT AND CONTINUED AND CONTINUED

THE INFORMATION CURTINITIES IN IT INTORNATION OF VARIOUS REPORTS IN THE INFORMATION IS PRESENTED TO THEIR OWN INVESTMENT OBJECTIVES, FINANCIAL STUDIES AND SEEK INDEPENDENT PROFESSIONAL ADVISOR SHOWLD CONSIDER A PROPRIATE TO THEIR UNING REGARD TO THEIR OWN INVESTMENT OBJECTIVES, FINANCIAL STUDIES AND SEEK INDEPENDENT PROFESSIONAL ADVISOR SHOWLD CONTINUED AND THE INVESTMENT OBJECTIVES, AND SEEK INDEPENDENT PROFESSIONAL ADVISOR SHOWLD CONTINUED AND THE INVESTMENT OBJECTIVES, AND SEEK INDEPENDENT PROFESSIONAL ADVISOR SHOWLD CONTINUED AND THE INVESTMENT OF THE INVESTME

REPRESENTATION ON WARRANTI, E. ST. SUBJECT, IS MADE BY A WARRANT, I. S. M. THE PROVINCE OF SOLD AND THE CONTROL OF SOLD OF MICE AND THE CONTROL OF SOLD OF MICH ARE BEYOND THE CONTROL OF SOL OF MICH ARE BEYOND THE CONTROL OF SOLD OF MICH ARE BY A MICH AND BY A MICH ARE BY A MICH ARE BY A MICH ARE BY A MICH ARE BY A MICH AND BY A MICH AND BY A MICH ARE BY A MICH AND BY A MICH ARE BY A MIC

COMPARABLE TERMINOLOGY. THESE FORWARD-LOCKING STATEMENTS INCLUDE ALL MATTERS THAT ARE NOT OTHISTORICAL FACTS. SUCH FORWARD-LOCKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTIANTIES AND OTHER FACTORS WHICH BECAUSE OF THEIR NATURE MAY CAUSE THE ACTUAL RESULTS OR PERFORMANCE OF SD TO BE MATERIAL TO PERFORMANCE OF THE PROPERTIES OF THE PROPERTIES OF THE RESULTS OR PERFORMANCE OF THE RESULTS OR PERFORMANCE OF THE PROPERTIES OR THE PERFORMANCE OF THE PROPERTIES OR THE PROPE

FIGURES SET OUT IN THIS PRESENTATION.